| Name | Title | Contact Details |
|---|
Jeffrey J Eckardt is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We believe affordable, convenient vision prescriptions are a good thing. We started Opternative to provide a safe, online option for vision testing. It`s a way to get prescriptions between eye exams. Eyes stay healthy. People can see clearly. It`s a win-win.
BehaVR is a new kind of digital therapeutics company dedicated to tackling the epidemic of anxiety-related challenges and disorders, to help curb chronic disease at scale. Partnering with the country`s leading academic institutions, research institutes and pharmaceutical companies, we innovate at the intersection of behavioral science, virtual reality and community design to develop immersive, evidence-based experiences that change peoples` lives. With every program we create, we commit to give people agency over their own health, and generate value, change, and better clinical outcomes for all stakeholders in the healthcare system.
HealthLogic Systems Corporation is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.